Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1702 in R/R AML or MDS
NCT04443751Phase 1Completed
- Sponsor
- Hengrui
- Start
- Sep 2020
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-1702 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Hengrui. Primary endpoint: Maximum Tolerated Dose / Recommended Phase 2 Dose at 6 months. Started Sep 2020; status: completed.
02
Drugs
SHR-1702
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04443751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04443751.